Eagle Health Investments LP Has $13.53 Million Position in Scholar Rock Holding Corporation $SRRK

Eagle Health Investments LP increased its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 34.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 363,300 shares of the company’s stock after acquiring an additional 93,900 shares during the quarter. Scholar Rock makes up approximately 3.6% of Eagle Health Investments LP’s portfolio, making the stock its 11th largest position. Eagle Health Investments LP’s holdings in Scholar Rock were worth $13,529,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SRRK. Penserra Capital Management LLC bought a new position in Scholar Rock in the 3rd quarter worth approximately $56,000. Strs Ohio bought a new stake in shares of Scholar Rock in the first quarter valued at approximately $77,000. Bessemer Group Inc. increased its position in Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock worth $86,000 after acquiring an additional 2,105 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Scholar Rock during the 2nd quarter valued at $94,000. Finally, AlphaQuest LLC boosted its holdings in Scholar Rock by 30.1% in the 3rd quarter. AlphaQuest LLC now owns 3,415 shares of the company’s stock valued at $127,000 after purchasing an additional 791 shares during the period. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of SRRK stock opened at $46.45 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The stock’s fifty day simple moving average is $45.08 and its 200 day simple moving average is $38.17. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of -14.75 and a beta of 0.67.

Analyst Ratings Changes

Several research firms have recently issued reports on SRRK. HC Wainwright boosted their price objective on shares of Scholar Rock from $44.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Barclays boosted their price target on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. raised their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Wolfe Research started coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, UBS Group initiated coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $51.14.

Insider Buying and Selling at Scholar Rock

In related news, General Counsel Junlin Ho sold 8,016 shares of Scholar Rock stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $44.48, for a total transaction of $356,551.68. Following the completion of the transaction, the general counsel directly owned 214,553 shares of the company’s stock, valued at $9,543,317.44. This trade represents a 3.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Caryn Parlavecchio sold 6,600 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total transaction of $293,568.00. Following the sale, the insider directly owned 148,864 shares in the company, valued at $6,621,470.72. This represents a 4.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 305,687 shares of company stock worth $13,540,573 over the last ninety days. Company insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).